Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024 Notified

Why in news

The Department of Pharmaceuticals has notified the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024, replacing the 2015 version, with amendments made in September 2025 to strengthen ethical marketing practices in the pharmaceutical sector.

Exam relevance

GS2, GS3 · Governance, Economy, Society · Prelims · Mains

Key facts

1. The Department of Pharmaceuticals notified the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024 on March 12, 2024.
2. The UCPMP, 2024 replaces the earlier UCPMP, 2015.
3. The Code was amended in September 2025.
4. The UCPMP, 2024 incorporates revised provisions to strengthen ethical marketing practices by pharmaceutical companies.
5. Key provisions include the constitution of Ethics Committees for Pharmaceutical Marketing Practices (ECPMPs) and appointment of Ethics Officers by companies.
6. It establishes a structured complaint redressal and appellate mechanism.
7. Companies are required to submit self-declarations regarding compliance and disclose prescribed marketing expenditure.
8. The Code has enhanced provisions for interactions between pharmaceutical companies and healthcare professionals/organizations regarding promotional activities.
9. Amendments in 2025 require companies to submit annual statements on marketing expenditure.

Prelims pointers

• The Uniform Code for Pharmaceutical Marketing Practices (UCPMP) is notified by the Department of Pharmaceuticals.
• UCPMP, 2024 replaces UCPMP, 2015.
• The Code mandates the formation of Ethics Committees for Pharmaceutical Marketing Practices (ECPMPs).
• Pharmaceutical companies are required to appoint Ethics Officers.
• The Code includes provisions for disclosure of marketing expenditure and self-declarations of compliance.
• Amendments in 2025 focus on streamlining implementation and disclosure requirements for marketing expenditure.

Mains practice question

Discuss the significance of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024 in ensuring ethical conduct within the pharmaceutical industry and its implications for public health in India.

Static linkage

The UCPMP is a self-regulatory code adopted by the pharmaceutical industry in India to govern marketing practices and ensure ethical conduct in interactions with healthcare professionals. It aims to curb unethical promotional activities and ensure transparency in the pharmaceutical sector, aligning with broader governance objectives related to public health and consumer protection.

Significance

The notification of UCPMP, 2024, with subsequent amendments, signifies a move towards greater transparency and ethical conduct in the pharmaceutical industry's marketing strategies. Enhanced provisions for disclosure of marketing expenditure and interactions with healthcare professionals are crucial for curbing potential conflicts of interest and ensuring that medical decisions are based on clinical evidence rather than promotional influence. The structured complaint redressal mechanism aims to improve accountability. This is significant for public health as it can lead to more rational drug use and potentially reduce healthcare costs associated with unethical marketing.